PMC:7144273 / 21314-22038 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T181","span":{"begin":164,"end":168},"obj":"Body_part"},{"id":"T182","span":{"begin":292,"end":296},"obj":"Body_part"},{"id":"T183","span":{"begin":349,"end":353},"obj":"Body_part"},{"id":"T184","span":{"begin":467,"end":472},"obj":"Body_part"},{"id":"T185","span":{"begin":473,"end":482},"obj":"Body_part"},{"id":"T186","span":{"begin":484,"end":486},"obj":"Body_part"},{"id":"T187","span":{"begin":535,"end":544},"obj":"Body_part"},{"id":"T188","span":{"begin":549,"end":552},"obj":"Body_part"},{"id":"T189","span":{"begin":572,"end":577},"obj":"Body_part"},{"id":"T190","span":{"begin":578,"end":588},"obj":"Body_part"},{"id":"T191","span":{"begin":593,"end":602},"obj":"Body_part"},{"id":"T192","span":{"begin":609,"end":613},"obj":"Body_part"},{"id":"T193","span":{"begin":609,"end":611},"obj":"Body_part"},{"id":"T194","span":{"begin":656,"end":664},"obj":"Body_part"},{"id":"T195","span":{"begin":665,"end":667},"obj":"Body_part"},{"id":"T196","span":{"begin":683,"end":688},"obj":"Body_part"}],"attributes":[{"id":"A181","pred":"fma_id","subj":"T181","obj":"http://purl.org/sig/ont/fma/fma50723"},{"id":"A182","pred":"fma_id","subj":"T182","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A183","pred":"fma_id","subj":"T183","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A184","pred":"fma_id","subj":"T184","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A185","pred":"fma_id","subj":"T185","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A186","pred":"fma_id","subj":"T186","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A187","pred":"fma_id","subj":"T187","obj":"http://purl.org/sig/ont/fma/fma241981"},{"id":"A188","pred":"fma_id","subj":"T188","obj":"http://purl.org/sig/ont/fma/fma20935"},{"id":"A189","pred":"fma_id","subj":"T189","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A190","pred":"fma_id","subj":"T190","obj":"http://purl.org/sig/ont/fma/fma241981"},{"id":"A191","pred":"fma_id","subj":"T191","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A192","pred":"fma_id","subj":"T192","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A193","pred":"fma_id","subj":"T193","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A194","pred":"fma_id","subj":"T194","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A195","pred":"fma_id","subj":"T195","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A196","pred":"fma_id","subj":"T196","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"Li, 2016 [16] C57BL/6 mice aged 6–8 weeks, i.n. infection, avian influenza virus Hong Kong/2108/2003 (H9N2) Mouse BM-MSCs (P3–P10), 1×105 cells·mouse−1, i.v. (tail vein), single dose, 30 min or day 1 post infection Day 3 No Regardless of time of administration, syngeneic MSCs did not reduce lung virus titration, increased survival rate, decreased lung oedema, decreased histological injury, and improved gas exchange; early and late administration reduced BALF and serum cytokines (IL-6 and TNF-α); early administration reduced BALF chemokine (GM-CSF), reduced BALF and serum chemokines and cytokines (MIG, IL-1α, IFN-γ), and increased anti-inflammatory cytokine IL-10 in BALF and serum Nonspecified (soluble mediators) No"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T63","span":{"begin":159,"end":168},"obj":"Body_part"},{"id":"T64","span":{"begin":159,"end":163},"obj":"Body_part"},{"id":"T65","span":{"begin":164,"end":168},"obj":"Body_part"},{"id":"T66","span":{"begin":292,"end":296},"obj":"Body_part"},{"id":"T67","span":{"begin":349,"end":353},"obj":"Body_part"},{"id":"T68","span":{"begin":467,"end":472},"obj":"Body_part"},{"id":"T69","span":{"begin":572,"end":577},"obj":"Body_part"},{"id":"T70","span":{"begin":683,"end":688},"obj":"Body_part"}],"attributes":[{"id":"A63","pred":"uberon_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/UBERON_0003481"},{"id":"A64","pred":"uberon_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/UBERON_0002415"},{"id":"A65","pred":"uberon_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/UBERON_0001638"},{"id":"A66","pred":"uberon_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A67","pred":"uberon_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A68","pred":"uberon_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A69","pred":"uberon_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A70","pred":"uberon_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Li, 2016 [16] C57BL/6 mice aged 6–8 weeks, i.n. infection, avian influenza virus Hong Kong/2108/2003 (H9N2) Mouse BM-MSCs (P3–P10), 1×105 cells·mouse−1, i.v. (tail vein), single dose, 30 min or day 1 post infection Day 3 No Regardless of time of administration, syngeneic MSCs did not reduce lung virus titration, increased survival rate, decreased lung oedema, decreased histological injury, and improved gas exchange; early and late administration reduced BALF and serum cytokines (IL-6 and TNF-α); early administration reduced BALF chemokine (GM-CSF), reduced BALF and serum chemokines and cytokines (MIG, IL-1α, IFN-γ), and increased anti-inflammatory cytokine IL-10 in BALF and serum Nonspecified (soluble mediators) No"}

{"project":"LitCovid_AGAC","denotations":[{"id":"p108674s63","span":{"begin":555,"end":562},"obj":"NegReg"},{"id":"p108674s87","span":{"begin":656,"end":670},"obj":"MPA"}],"text":"Li, 2016 [16] C57BL/6 mice aged 6–8 weeks, i.n. infection, avian influenza virus Hong Kong/2108/2003 (H9N2) Mouse BM-MSCs (P3–P10), 1×105 cells·mouse−1, i.v. (tail vein), single dose, 30 min or day 1 post infection Day 3 No Regardless of time of administration, syngeneic MSCs did not reduce lung virus titration, increased survival rate, decreased lung oedema, decreased histological injury, and improved gas exchange; early and late administration reduced BALF and serum cytokines (IL-6 and TNF-α); early administration reduced BALF chemokine (GM-CSF), reduced BALF and serum chemokines and cytokines (MIG, IL-1α, IFN-γ), and increased anti-inflammatory cytokine IL-10 in BALF and serum Nonspecified (soluble mediators) No"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T168","span":{"begin":48,"end":57},"obj":"Disease"},{"id":"T169","span":{"begin":59,"end":74},"obj":"Disease"},{"id":"T170","span":{"begin":65,"end":74},"obj":"Disease"},{"id":"T171","span":{"begin":205,"end":214},"obj":"Disease"},{"id":"T172","span":{"begin":385,"end":391},"obj":"Disease"}],"attributes":[{"id":"A168","pred":"mondo_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A169","pred":"mondo_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/MONDO_0018695"},{"id":"A170","pred":"mondo_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A171","pred":"mondo_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A172","pred":"mondo_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"}],"text":"Li, 2016 [16] C57BL/6 mice aged 6–8 weeks, i.n. infection, avian influenza virus Hong Kong/2108/2003 (H9N2) Mouse BM-MSCs (P3–P10), 1×105 cells·mouse−1, i.v. (tail vein), single dose, 30 min or day 1 post infection Day 3 No Regardless of time of administration, syngeneic MSCs did not reduce lung virus titration, increased survival rate, decreased lung oedema, decreased histological injury, and improved gas exchange; early and late administration reduced BALF and serum cytokines (IL-6 and TNF-α); early administration reduced BALF chemokine (GM-CSF), reduced BALF and serum chemokines and cytokines (MIG, IL-1α, IFN-γ), and increased anti-inflammatory cytokine IL-10 in BALF and serum Nonspecified (soluble mediators) No"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T317","span":{"begin":0,"end":2},"obj":"http://purl.obolibrary.org/obo/CLO_0001022"},{"id":"T318","span":{"begin":0,"end":2},"obj":"http://purl.obolibrary.org/obo/CLO_0007314"},{"id":"T319","span":{"begin":75,"end":80},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T320","span":{"begin":108,"end":113},"obj":"http://purl.obolibrary.org/obo/CLO_0007836"},{"id":"T321","span":{"begin":114,"end":116},"obj":"http://purl.obolibrary.org/obo/CLO_0001997"},{"id":"T322","span":{"begin":132,"end":137},"obj":"http://purl.obolibrary.org/obo/CLO_0001040"},{"id":"T323","span":{"begin":159,"end":163},"obj":"http://purl.obolibrary.org/obo/UBERON_0002415"},{"id":"T324","span":{"begin":164,"end":168},"obj":"http://purl.obolibrary.org/obo/UBERON_0001638"},{"id":"T325","span":{"begin":164,"end":168},"obj":"http://www.ebi.ac.uk/efo/EFO_0000816"},{"id":"T326","span":{"begin":292,"end":296},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T327","span":{"begin":292,"end":296},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T328","span":{"begin":297,"end":302},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T329","span":{"begin":349,"end":353},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T330","span":{"begin":349,"end":353},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"Li, 2016 [16] C57BL/6 mice aged 6–8 weeks, i.n. infection, avian influenza virus Hong Kong/2108/2003 (H9N2) Mouse BM-MSCs (P3–P10), 1×105 cells·mouse−1, i.v. (tail vein), single dose, 30 min or day 1 post infection Day 3 No Regardless of time of administration, syngeneic MSCs did not reduce lung virus titration, increased survival rate, decreased lung oedema, decreased histological injury, and improved gas exchange; early and late administration reduced BALF and serum cytokines (IL-6 and TNF-α); early administration reduced BALF chemokine (GM-CSF), reduced BALF and serum chemokines and cytokines (MIG, IL-1α, IFN-γ), and increased anti-inflammatory cytokine IL-10 in BALF and serum Nonspecified (soluble mediators) No"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T119","span":{"begin":0,"end":2},"obj":"Chemical"},{"id":"T120","span":{"begin":484,"end":486},"obj":"Chemical"},{"id":"T122","span":{"begin":546,"end":548},"obj":"Chemical"},{"id":"T123","span":{"begin":609,"end":611},"obj":"Chemical"},{"id":"T125","span":{"begin":616,"end":619},"obj":"Chemical"},{"id":"T126","span":{"begin":665,"end":667},"obj":"Chemical"}],"attributes":[{"id":"A119","pred":"chebi_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/CHEBI_30145"},{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A121","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A122","pred":"chebi_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/CHEBI_74120"},{"id":"A123","pred":"chebi_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A124","pred":"chebi_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A125","pred":"chebi_id","subj":"T125","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A126","pred":"chebi_id","subj":"T126","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A127","pred":"chebi_id","subj":"T126","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Li, 2016 [16] C57BL/6 mice aged 6–8 weeks, i.n. infection, avian influenza virus Hong Kong/2108/2003 (H9N2) Mouse BM-MSCs (P3–P10), 1×105 cells·mouse−1, i.v. (tail vein), single dose, 30 min or day 1 post infection Day 3 No Regardless of time of administration, syngeneic MSCs did not reduce lung virus titration, increased survival rate, decreased lung oedema, decreased histological injury, and improved gas exchange; early and late administration reduced BALF and serum cytokines (IL-6 and TNF-α); early administration reduced BALF chemokine (GM-CSF), reduced BALF and serum chemokines and cytokines (MIG, IL-1α, IFN-γ), and increased anti-inflammatory cytokine IL-10 in BALF and serum Nonspecified (soluble mediators) No"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T63","span":{"begin":410,"end":418},"obj":"http://purl.obolibrary.org/obo/GO_0015297"}],"text":"Li, 2016 [16] C57BL/6 mice aged 6–8 weeks, i.n. infection, avian influenza virus Hong Kong/2108/2003 (H9N2) Mouse BM-MSCs (P3–P10), 1×105 cells·mouse−1, i.v. (tail vein), single dose, 30 min or day 1 post infection Day 3 No Regardless of time of administration, syngeneic MSCs did not reduce lung virus titration, increased survival rate, decreased lung oedema, decreased histological injury, and improved gas exchange; early and late administration reduced BALF and serum cytokines (IL-6 and TNF-α); early administration reduced BALF chemokine (GM-CSF), reduced BALF and serum chemokines and cytokines (MIG, IL-1α, IFN-γ), and increased anti-inflammatory cytokine IL-10 in BALF and serum Nonspecified (soluble mediators) No"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T28","span":{"begin":354,"end":360},"obj":"Phenotype"}],"attributes":[{"id":"A28","pred":"hp_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/HP_0000969"}],"text":"Li, 2016 [16] C57BL/6 mice aged 6–8 weeks, i.n. infection, avian influenza virus Hong Kong/2108/2003 (H9N2) Mouse BM-MSCs (P3–P10), 1×105 cells·mouse−1, i.v. (tail vein), single dose, 30 min or day 1 post infection Day 3 No Regardless of time of administration, syngeneic MSCs did not reduce lung virus titration, increased survival rate, decreased lung oedema, decreased histological injury, and improved gas exchange; early and late administration reduced BALF and serum cytokines (IL-6 and TNF-α); early administration reduced BALF chemokine (GM-CSF), reduced BALF and serum chemokines and cytokines (MIG, IL-1α, IFN-γ), and increased anti-inflammatory cytokine IL-10 in BALF and serum Nonspecified (soluble mediators) No"}

{"project":"LitCovid-sentences","denotations":[{"id":"T101","span":{"begin":0,"end":724},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Li, 2016 [16] C57BL/6 mice aged 6–8 weeks, i.n. infection, avian influenza virus Hong Kong/2108/2003 (H9N2) Mouse BM-MSCs (P3–P10), 1×105 cells·mouse−1, i.v. (tail vein), single dose, 30 min or day 1 post infection Day 3 No Regardless of time of administration, syngeneic MSCs did not reduce lung virus titration, increased survival rate, decreased lung oedema, decreased histological injury, and improved gas exchange; early and late administration reduced BALF and serum cytokines (IL-6 and TNF-α); early administration reduced BALF chemokine (GM-CSF), reduced BALF and serum chemokines and cytokines (MIG, IL-1α, IFN-γ), and increased anti-inflammatory cytokine IL-10 in BALF and serum Nonspecified (soluble mediators) No"}

{"project":"LitCovid-PubTator","denotations":[{"id":"729","span":{"begin":665,"end":670},"obj":"Gene"},{"id":"756","span":{"begin":108,"end":113},"obj":"Species"},{"id":"790","span":{"begin":205,"end":214},"obj":"Disease"},{"id":"791","span":{"begin":339,"end":360},"obj":"Disease"}],"attributes":[{"id":"A729","pred":"tao:has_database_id","subj":"729","obj":"Gene:16153"},{"id":"A756","pred":"tao:has_database_id","subj":"756","obj":"Tax:10090"},{"id":"A790","pred":"tao:has_database_id","subj":"790","obj":"MESH:D007239"},{"id":"A791","pred":"tao:has_database_id","subj":"791","obj":"MESH:D004487"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Li, 2016 [16] C57BL/6 mice aged 6–8 weeks, i.n. infection, avian influenza virus Hong Kong/2108/2003 (H9N2) Mouse BM-MSCs (P3–P10), 1×105 cells·mouse−1, i.v. (tail vein), single dose, 30 min or day 1 post infection Day 3 No Regardless of time of administration, syngeneic MSCs did not reduce lung virus titration, increased survival rate, decreased lung oedema, decreased histological injury, and improved gas exchange; early and late administration reduced BALF and serum cytokines (IL-6 and TNF-α); early administration reduced BALF chemokine (GM-CSF), reduced BALF and serum chemokines and cytokines (MIG, IL-1α, IFN-γ), and increased anti-inflammatory cytokine IL-10 in BALF and serum Nonspecified (soluble mediators) No"}